Immunotherapy of hepatocellular carcinoma

References

• Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol.27(9), 1485–1491 (2009).
   PubMed Web of Science ®Google Scholar
• Greten TF, Papendorf F, Bleck JS et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br. J. Cancer92(10), 1862–1868 (2005).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology134(6), 1752–1763 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas MB, O’Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann. Surg. Oncol.15(4), 1008–1014 (2008).
   PubMed Web of Science ®Google Scholar
• Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer100(1), 19–23 (2009).
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer immunology. N. Engl. J. Med.358(25), 2704–2715 (2008).
   PubMed Web of Science ®Google Scholar
• Greten TF, Manns MP, Korangy F. Immunotherapy of HCC. Rev. Recent Clin. Trials3(1), 31–39 (2008).
   PubMedGoogle Scholar
• Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med.336(26), 1855–1859 (1997).
   PubMed Web of Science ®Google Scholar
• Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol.5(3), 215–229 (2005).
   PubMed Web of Science ®Google Scholar
• Naugler WE, Sakurai T, Kim S et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science317(5834), 121–124 (2007).
   PubMed Web of Science ®Google Scholar
• Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology27(2), 407–414 (1998).
   PubMed Web of Science ®Google Scholar
• Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology132(7), 2328–2339 (2007).
   PubMed Web of Science ®Google Scholar
• Gao Q, Qiu SJ, Fan J et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol.25(18), 2586–2593 (2007).
   PubMed Web of Science ®Google Scholar
• Unitt E, Marshall A, Gelson W et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J. Hepatol.45(2), 246–253 (2006).
   PubMed Web of Science ®Google Scholar
• Chew V, Tow C, Teo M et al. Inflammatory tumor microenvironment is associated with superior survival in hepatocellular carcinoma patients. J. Hepatol.52(3), 370–379 (2010).
   PubMed Web of Science ®Google Scholar
• Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell10(2), 99–111 (2006).
   PubMed Web of Science ®Google Scholar
• Gao Q, Wang XY, Qiu SJ et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res.15(3), 971–979 (2009).
   PubMed Web of Science ®Google Scholar
• Blondon H, Fritsch L, Cherqui D. Two cases of spontaneous regression of multicentric hepatocellular carcinoma after intraperitoneal rupture: possible role of immune mechanisms. Eur. J. Gastroenterol. Hepatol.16(12), 1355–1359 (2004).
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Ribas A, Meng WS et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from α-fetoprotein in patients with hepatocellular cancer. Clin. Cancer Res.9(16 Pt 1), 5902–5908 (2003).
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Ribas A, Dissette VB et al. A Phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides. Clin. Cancer Res.12(9), 2817–2825 (2006).
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Ribas A, Potter DM, Economou JS. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol. Immunother.56(12), 1931–1943 (2007).
   PubMed Web of Science ®Google Scholar
• Kong J, Diao Z, Deng X, Zhong H, Yao W, Hu X. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier. Oncol. Rep.18(1), 279–285 (2007).
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Koh A, Meng W et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from α-fetoprotein. Cancer Res.59(13), 3134–3142 (1999).
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Meng WS, Koh A et al. T cell responses to HLA-A*0201-restricted peptides derived from human a fetoprotein. J. Immunol.166(8), 5300–5308 (2001).
   PubMed Web of Science ®Google Scholar
• Meng WS, Butterfield LH, Ribas A et al. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human α-fetoprotein. Mol. Immunol.37(16), 943–950 (2000).
   PubMed Web of Science ®Google Scholar
• Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of α-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int. J. Cancer118(5), 1194–1204 (2006).
   PubMed Web of Science ®Google Scholar
• Alisa A, Ives A, Pathan AA et al. Analysis of CD4+ T-cell responses to a novel α-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin. Cancer Res.11(18), 6686–6694 (2005).
   PubMed Web of Science ®Google Scholar
• Thimme R, Neagu M, Boettler T et al. Comprehensive analysis of the α-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology48(6), 1821–1833 (2008).
   PubMed Web of Science ®Google Scholar
• Bricard G, Bouzourene H, Martinet O et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J. Immunol.174(3), 1709–1716 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang HG, Chen HS, Peng JR et al. Specific CD8+ T cell responses to HLA-A2 restricted MAGE-A3 p271–279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol. Immunother.56(12), 1945–1954 (2007).
   PubMed Web of Science ®Google Scholar
• Riener MO, Wild PJ, Soll C et al. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int. J. Cancer124(2), 352–357 (2009).
   PubMed Web of Science ®Google Scholar
• Korangy F, Ormandy LA, Bleck JS et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin. Cancer Res.10(13), 4332–4341 (2004).
   PubMed Web of Science ®Google Scholar
• Peng JR, Chen HS, Mou DC et al. Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett.219(2), 223–232 (2005).
   PubMed Web of Science ®Google Scholar
• Chen HS, Qin LL, Cong X et al. Expression of tumor-specific cancer/testis antigens in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi11(3), 145–148 (2003).
   PubMedGoogle Scholar
• Shang XY, Chen HS, Zhang HG et al. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin. Cancer Res.10(20), 6946–6955 (2004).
   PubMed Web of Science ®Google Scholar
• Chen CH, Chen GJ, Lee HS et al. Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett.164(2), 189–195 (2001).
   PubMed Web of Science ®Google Scholar
• Gehring AJ, Ho ZZ, Tan AT et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology137(2), 682–690 (2009).
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity10(6), 673–679 (1999).
   PubMed Web of Science ®Google Scholar
• Miura N, Horikawa I, Nishimoto A et al. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet. Cytogenet.93(1), 56–62 (1997).
   PubMed Web of Science ®Google Scholar
• Miura N, Maeda Y, Kanbe T et al. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin. Cancer Res.11(9), 3205–3209 (2005).
   PubMed Web of Science ®Google Scholar
• Mizukoshi E, Nakamoto Y, Marukawa Y et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology43(6), 1284–1294 (2006).
   PubMed Web of Science ®Google Scholar
• Nakamoto Y, Mizukoshi E, Tsuji H et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin. Exp. Immunol.147(2), 296–305 (2007).
   PubMed Web of Science ®Google Scholar
• Hiroishi K, Eguchi J, Baba T et al. Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J. Gastroenterol.45(4), 451–458 (2009).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Powrie F. Emerging challenges in regulatory T cell function and biology. Science317(5838), 627–629 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int. J. Cancer125(7), 1640–1648 (2009).
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol. Immunother.56(3), 271–285 (2007).
   PubMed Web of Science ®Google Scholar
• Audia S, Nicolas A, Cathelin D et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin. Exp. Immunol.150(3), 523–530 (2007).
   PubMed Web of Science ®Google Scholar
• Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res.65(6), 2457–2464 (2005).
   PubMed Web of Science ®Google Scholar
• Unitt E, Rushbrook SM, Marshall A et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology41(4), 722–730 (2005).
   PubMed Web of Science ®Google Scholar
• Yang XH, Yamagiwa S, Ichida T et al. Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J. Hepatol.45(2), 254–262 (2006).
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med.198(12), 1875–1886 (2003).
   PubMed Web of Science ®Google Scholar
• Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology28(1), 68–77 (1998).
   PubMed Web of Science ®Google Scholar
• Beckebaum S, Zhang X, Chen X et al. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin. Cancer Res.10(21), 7260–7269 (2004).
   PubMed Web of Science ®Google Scholar
• Giannelli G, Fransvea E, Marinosci F et al. Transforming growth factor-β1 triggers hepatocellular carcinoma invasiveness via α3β1 integrin. Am. J. Pathol.161(1), 183–193 (2002).
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol.163(10), 5211–5218 (1999).
   PubMed Web of Science ®Google Scholar
• Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol.32(11), 3267–3275 (2002).
   PubMed Web of Science ®Google Scholar
• Shimizu K, Fields RC, Giedlin M, Mule JJ. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl Acad. Sci. USA96(5), 2268–2273 (1999).
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Larmonier N, Schmitt E et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol.34(2), 336–344 (2004).
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest.115(12), 3623–3633 (2005).
   PubMed Web of Science ®Google Scholar
• Greten TF, Ormandy L, Fikuart A et al. Low dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T cell responses in patients with advanced HCC. J. Immunother.33(2), 211–218 (2010).
   PubMed Web of Science ®Google Scholar
• Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol.4(12), 941–952 (2004).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res.3(3), 483–490 (1997).
   PubMed Web of Science ®Google Scholar
• Ishida T, Oyama T, Carbone DP, Gabrilovich DI. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J. Immunol.161(9), 4842–4851 (1998).
   PubMed Web of Science ®Google Scholar
• Ormandy LA, Farber A, Cantz T et al. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J. Gastroenterol.12(20), 3275–3282 (2006).
   PubMed Web of Science ®Google Scholar
• Kakumu S, Ito S, Ishikawa T et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J. Gastroenterol. Hepatol.15(4), 431–436 (2000).
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J. Hepatol.31(2), 323–331 (1999).
   PubMed Web of Science ®Google Scholar
• Chen S, Akbar SM, Tanimoto K et al. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett.148(1), 49–57 (2000).
   PubMed Web of Science ®Google Scholar
• Tang TJ, Vukosavljevic D, Janssen HL et al. Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma. Hum. Pathol.37(3), 332–338 (2006).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res.5(10), 2963–2970 (1999).
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood92(11), 4150–4166 (1998).
   PubMed Web of Science ®Google Scholar
• Ohm JE, Shurin MR, Esche C, Lotze MT, Carbone DP, Gabrilovich DI. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J. Immunol.163(6), 3260–3268 (1999).
   PubMed Web of Science ®Google Scholar
• Menetrier-Caux C, Montmain G, Dieu MC et al. Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood92(12), 4778–4791 (1998).
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood100(1), 230–237 (2002).
   PubMed Web of Science ®Google Scholar
• Park SJ, Nakagawa T, Kitamura H et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol.173(6), 3844–3854 (2004).
   PubMed Web of Science ®Google Scholar
• Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res.63(9), 2150–2157 (2003).
   PubMed Web of Science ®Google Scholar
• Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J. Immunol.154(3), 1280–1286 (1995).
   PubMed Web of Science ®Google Scholar
• Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH. CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood99(7), 2468–2476 (2002).
   PubMed Web of Science ®Google Scholar
• Um SH, Mulhall C, Alisa A et al. α-fetoprotein impairs APC function and induces their apoptosis. J. Immunol.173(3), 1772–1778 (2004).
   PubMed Web of Science ®Google Scholar
• Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34+ cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res.1(1), 95–103 (1995).
   PubMed Web of Science ®Google Scholar
• Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol.166(1), 678–689 (2001).
   PubMed Web of Science ®Google Scholar
• Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol.16(1), 53–65 (2006).
   PubMed Web of Science ®Google Scholar
• Zea AH, Rodriguez PC, Atkins MB et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res.65(8), 3044–3048 (2005).
   PubMed Web of Science ®Google Scholar
• Filipazzi P, Valenti R, Huber V et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol.25(18), 2546–2553 (2007).
   PubMed Web of Science ®Google Scholar
• Serafini P, Meckel K, Kelso M et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med.203(12), 2691–2702 (2006).
   PubMed Web of Science ®Google Scholar
• Mirza N, Fishman M, Fricke I et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res.66(18), 9299–9307 (2006).
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells – conductors of tumor immunity? Curr. Opin. Immunol.14(2), 165–171 (2002).
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med.201(12), 1973–1985 (2005).
   PubMed Web of Science ®Google Scholar
• Cai L, Zhang Z, Zhou L et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin. Immunol.129(3), 428–437 (2008).
   PubMed Web of Science ®Google Scholar
• Hoechst B, Voigtlaender T, Ormandy L et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology50(3), 799–807 (2009).
   PubMed Web of Science ®Google Scholar
• Subleski JJ, Hall VL, Back TC, Ortaldo JR, Wiltrout RH. Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res.66(22), 11005–11012 (2006).
   PubMed Web of Science ®Google Scholar
• Tsuchiyama T, Nakamoto Y, Sakai Y et al. Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma. J. Immunol.178(1), 574–583 (2007).
   PubMed Web of Science ®Google Scholar
• Bricard G, Cesson V, Devevre E et al. Enrichment of human CD4+ V(a)24/Vb11 invariant NKT cells in intrahepatic malignant tumors. J. Immunol.182(8), 5140–5151 (2009).
   PubMed Web of Science ®Google Scholar
• Takikawa O, Yoshida R, Kido R, Hayaishi O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J. Biol. Chem.261(8), 3648–3653 (1986).
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest.117(5), 1147–1154 (2007).
   PubMed Web of Science ®Google Scholar
• Pan K, Wang H, Chen MS et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol.134(11), 1247–1253 (2008).
   PubMed Web of Science ®Google Scholar
• Ishio T, Goto S, Tahara K, Tone S, Kawano K, Kitano S. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J. Gastroenterol. Hepatol.19(3), 319–326 (2004).
   PubMed Web of Science ®Google Scholar
• Cheng AS, Chan HL, To KF et al. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int. J. Oncol.24(4), 853–860 (2004).
   PubMed Web of Science ®Google Scholar
• Tang TC, Poon RT, Lau CP, Xie D, Fan ST. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J. Gastroenterol.11(13), 1896–1902 (2005).
   PubMed Web of Science ®Google Scholar
• Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res.58(22), 4997–5001 (1998).
   PubMed Web of Science ®Google Scholar
• Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J. Natl Cancer Inst.90(21), 1609–1620 (1998).
   PubMedGoogle Scholar
• Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl Cancer Inst.90(20), 1529–1536 (1998).
   PubMed Web of Science ®Google Scholar
• Iwamoto A, Ikeguchi M, Matsumoto S et al. Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma. Tumori92(2), 130–133 (2006).
   PubMed Web of Science ®Google Scholar
• Palmer DH, Midgley RS, Mirza N et al. A Phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology49(1), 124–132 (2009).
   PubMed Web of Science ®Google Scholar
• Mizukoshi E, Nakamoto Y, Arai K et al. Enhancement of tumor-specific T cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int. J. Cancer126(9), 2164–2174 (2010).
   PubMed Web of Science ®Google Scholar
• Zerbini A, Pilli M, Fagnoni F et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J. Immunother.31(3), 271–282 (2008).
   PubMed Web of Science ®Google Scholar
• Ali MY, Grimm CF, Ritter M et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J. Hepatol.43(5), 817–822 (2005).
   PubMed Web of Science ®Google Scholar
• Zerbini A, Pilli M, Laccabue D et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology138(5), 1931–1942 (2010).
   PubMed Web of Science ®Google Scholar
• Zerbini A, Pilli M, Penna A et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res.66(2), 1139–1146 (2006).
   PubMed Web of Science ®Google Scholar
• Ayaru L, Pereira SP, Alisa A et al. Unmasking of α-fetoprotein-specific CD4+ T cell responses in hepatocellular carcinoma patients undergoing embolization. J. Immunol.178(3), 1914–1922 (2007).
   PubMed Web of Science ®Google Scholar
• Ji J, Shi J, Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med.361(15), 1437–1447 (2009).
   PubMed Web of Science ®Google Scholar